Advances in the Influence of EGFR Mutation on the PD-L1 Expression in Non-small Cell Lung Cancer

Advances in the Influence of EGFR Mutation on the PD-L1 Expression in Non-small Cell Lung Cancer

Researches on the inhibitors of programmed death-1 (PD-1) and programmed death-1 ligand (PD-L1) enjoy considerable breakthroughs in recent years, which has brought relative changes in the therapeutic model of non-small cell lung cancer (NSCLC) at an unexpected speed. However, it seems that PD-1/PD-L...

Full description

Bibliographic Details
Main Authors:	Xiaoyu ZHI, Weiwei LI, Shaowei WANG, Jinliang WANG
Format:	Article
Language:	zho
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2019-12-01
Series:	Chinese Journal of Lung Cancer
Subjects:	egfr mutation pd-1/pd-l1 inhibitors lung neoplasms pd-l1
Online Access:	http://dx.doi.org/10.3779/j.issn.1009-3419.2019.12.08

Similar Items

Study Progression on Non-small Cell Lung Cancer with EGFR Mutation  Treated by Immune Checkpoint Inhibitors
by: Rilan BAI, et al.
Published: (2018-08-01)

Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression
by: Yiran Cai, et al.
Published: (2020-02-01)

Clinical Analysis of Docetaxel Combined with PD-1/PD-L1 Inhibitor in Second-line Treatment of Advanced Non-small Cell Lung Cancer
by: Qing CHEN, et al.
Published: (2021-09-01)

Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma
by: Young Wha Koh, et al.
Published: (2023-03-01)

The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer
by: Vesna Ćeriman Krstić, et al.
Published: (2025-01-01)

EGFR mutation: novel prognostic factor associated with immune infiltration in lower-grade glioma; an exploratory study
by: Zhaonian Hao, et al.
Published: (2019-12-01)

Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for  Non-small Cell Lung Cancer
by: Sixuan WU, et al.
Published: (2019-07-01)

Progress of Immunotherapy Mechanisms and Current Evidence of PD-1/PD-L1  Checkpoint Inhibitors for Non-small Cell Lung Cancer with Brain Metastasis
by: Jiamin SHENG, et al.
Published: (2020-11-01)

Prospect and Current Situation of Immune Checkpoint Inhibitors  in First-line Treatment in Advanced Non-small Cell Lung Cancer Patients
by: Haiyang WANG, et al.
Published: (2017-06-01)

The relationship between PD-L1 expression and tumor driver gene mutations and survival in non small cell lung carcinoma
by: Kin Chan, et al.
Published: (2022-01-01)

Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
by: Kenneth K. W. To, et al.
Published: (2021-05-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
by: Hongbo Zhang, et al.
Published: (2021-06-01)

Evaluation of ALK, EGFR and PD-L1 Mutations in Pulmonary Carcinomas through Immunohistochemistry
by: Teona Bushati, et al.
Published: (2023-07-01)

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations
by: Anqi Lin, et al.
Published: (2019-09-01)

The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
by: He Ba, et al.
Published: (2021-11-01)

Research Advances of Immunotherapy of Exosome PD-L1  in Non-small Cell Lung Cancer
by: Na WANG, et al.
Published: (2022-09-01)

Immunotherapy protocols in lung cancer
by: Nandini Menon, et al.
Published: (2018-01-01)

Genetic dissection of intratumor heterogeneity of PD‐L1 expression in EGFR‐mutated lung adenocarcinoma
by: Kei Kunimasa, et al.
Published: (2023-08-01)

Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)
by: Caicun ZHOU, et al.
Published: (2020-02-01)

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
by: Ofek Mussafi, et al.
Published: (2022-08-01)

Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers
by: Chong Kin LIAM, et al.
Published: (2023-07-01)

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma
by: Yu-Min Zhong, et al.
Published: (2022-10-01)

Predictive Markers for Treating Efficacy of PD-1/PD-L1 Inhibitors in Patients with Lung Cancer: A Review of the 18th World Conference on Lung Cancer
by: Guanxuan CHEN, et al.
Published: (2018-09-01)

Heterogeneity in PD-L1 expression between primary and metastatic lymph nodes: a predictor of EGFR-TKI therapy response in non-small cell lung cancer
by: Yaohua Hu, et al.
Published: (2024-06-01)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01)

Efficacy of PD-1 or PD-L1 inhibitors for the therapy of cervical cancer with varying PD-L1 expression levels: a single-arm meta-analysis
by: Jie Yang, et al.
Published: (2024-08-01)

Predictive Value of Tumor Mutation Burden for PD-1/PD-L1 Inhibitors Treatment on Non-small Cell Lung Cancer: A Meta-analysis
by: SHEN Shijun, et al.
Published: (2021-03-01)

Research Progress of PD-1/PD-L1/2 Pathway in Multiple Myeloma
by: MA Yinjuan, et al.
Published: (2021-06-01)

Evaluation on the Distribution of EGFR, KRAS and BRAF Genes and the Expression of PD-L1 in Different Types of Lung Cancer
by: Zhao R, et al.
Published: (2021-09-01)

In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors
by: Boris Klebansky, et al.
Published: (2024-05-01)

Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
by: Runsen Jin, et al.
Published: (2020-08-01)

PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
by: Min Luo, et al.
Published: (2021-10-01)

Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors
by: Qian Chen, et al.
Published: (2022-08-01)

Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer
by: Naoya Nishioka, et al.
Published: (2022-05-01)

Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
by: Yijun Jia, et al.
Published: (2020-08-01)

Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation–Positive Lung Adenocarcinoma
by: Taehee Kim, M.D., et al.
Published: (2020-01-01)

It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC
by: Ken Akao, et al.
Published: (2024-07-01)

Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody
by: Kohei Fujita, et al.
Published: (2020-01-01)

Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer
by: Wang X, et al.
Published: (2023-01-01)

Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
by: Jue Zhu, et al.
Published: (2021-08-01)